Anonyme

🧬🍾🍷🥗

[HollywoodLife @HollywoodLife]

Pedro Pascal kicked off Pride Month with a message on Instagram. Happy Pride! 🏳️‍🌈
(📸: Getty Images)

[shelby @thetrueshelby]

Wanna piss off some bigots? 🌈

[Trinity College @TrinCollCam]

On Saturday evening members of the Trinity College Cambridge community gathered to celebrate the illumination of the Wren Library to mark the start of LGBTQ+ Pride Month.

Happy Pride! 🏳️‍🌈

[Pope Leo XIV @Pontifex]

In the era of #ArtificialIntelligence, when human dignity is threatened by new forms of dehumanization, ours is the pressing duty to remain profoundly human. We must lovingly safeguard the grandeur of humanity bestowed upon us and revealed in its fullness in Christ, the splendor of which no machine can ever replace. #MagnificaHumanitas
https://t.co/6i9MWs6LJl

[josh hardman @Josh__Hardman]

Never a quiet day!

A leadership vacuum at FDA sees former Usona Institute Chief Medical Officer Mike Davis, who is apparently very popular with agency staffers, assume the position of Acting Director of CDER (the body that is responsible for drug reviews).

[AtaiBeckley Inc @ataibeckley]

Today we announced the full Phase 2a results for EMP‑01 (oral R‑MDMA) in adults with Social Anxiety Disorder.

Results from the study (N=70) showed clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes.

Read the full announcement: https://t.co/Fpqv5uo5TE

$ATAI #EMP01 #SocialAnxietyDisorder #Biotech #MentalHealth

[The New York Times @nytimes]

Breaking News: President Trump ordered U.S. agencies to loosen restrictions on psychedelic drugs, in a move aimed at accelerating research. https://t.co/7TU6I7ezkA

[Michael Pollan @michaelpollan]

Trump plans to ease access to psychedelics like psilocybin, ibogaine https://t.co/iEnLlOvMpB

[nature @Nature]

Hundreds of scans hint at how substances such as psilocybin, LSD and ayahuasca alter connections between key areas of the brain

https://t.co/0KxphjMcld

[Eric Topol @EricTopol]

Two systematic, meta-analyses on psychedelic drugs today
Brain Circuit Function @NatureMedicine
https://t.co/nBmjreYEXU
Depression @NatMentHealth
https://t.co/zJR06AsC0Z

[Christian Angermayer @C_Angermayer]

$ATAI is currently covered by 13 analysts, with price targets spanning $7 to $25.

I believe though that the view of most investors and analysts on @ataibeckley appears largely anchored only to the initial lead indication and drug we are pursuing: treatment-resistant depression (TRD) for BPL-003 (5-MeO-DMT).

In my view, they underappreciate the broader product portfolio, including VLS-01 (DMT) for TRD and EMP-01 (R-MDMA) for social anxiety disorder, but more importantly, I believe they materially underestimate the long-term total addressable market (TAM) for psychedelic medicines.

IMO, one structural factor could ultimately expand that TAM significantly: Many serious diseases are far easier to prevent than to treat after onset. While this may sound obvious, the traditional healthcare system has largely been built around treating illness rather than preventing it.

That paradigm is beginning to change. The rapid adoption of GLP-1 drugs from $LLY and $NVO demonstrates how quickly the market can shift toward preventive and even lifestyle-enhancing medicine.

Read more about it in my latest blog post:

[Anonyme @BiotechFischer]

https://t.co/3Z7MjaRLHZ via @NYTimes Some of us worked for decades to make HIV treatment and prevention available globally for free without compromise or trade-offs. I am literally virtually sick!

[Christian Angermayer @C_Angermayer]

The time for psychedelics is now. $ATAI

[Anonyme @BiotechFischer]

@satyanadella Verily did that 10 years ago and we published the paper on virtual staining for liver disease!

[Meidas_Charise Lee @charise_lee]

#PamBondi

[Michael Pollan @michaelpollan]

AtaiBeckley’s MDMA product could treat social anxiety; HHS Secretary Kennedy talks psychedelics on Rogan podcast; WV Senate and SD legislature pass Compass trigger bills https://t.co/ZSLSUJJNyt

[Christian Angermayer @C_Angermayer]

No surprise - given the excellent data set that @ataibeckley's lead program, BPL-003, delivered in its Phase 2b study last year, and the recent FDA Breakthrough Therapy designation for treatment-resistant depression - but nevertheless a major milestone:

$ATAI has announced a successful End-of-Phase 2b meeting with the FDA regarding the development of BPL-003 for treatment-resistant depression.

This represents an important regulatory validation of both the data package and the planned path forward.

Now BPL-003 is rapidly advancing toward Phase 3 initiation in Q2 2026.

Don’t miss our Virtual Investor Day on March 6, 2026, where we will provide further insights into the Phase 3 design, as well as updates on our two other lead programs, VLS-01 and EMP-01.

Exciting days ahead 🚀

[Protect Kamala Harris ✊ @DisavowTrump20]

🚨NEW: James Talarico has won the Democratic primary for the U.S. Senate race in Texas.

RETWEET if you support @JamesTalarico and donate below to help him flip Texas Blue!